Skip to main content
GoodMoatv1.3
Sign in
BCRX logo

BCRX

CompareEarnings: May 31, 2026

Biocryst Pharmaceuticals Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.

Did you know?

BCRX's revenue grew at a 61.8% CAGR over the last 6 years.

Current Price

$9.19

+0.33%
Profile
Valuation (TTM)
Market Cap$1.93B
P/E7.33
EV—
P/B—
Shares Out210.54M
P/Sales2.21
Revenue$874.84M
EV/EBITDA6.15

Biocryst Pharmaceuticals Inc (BCRX) Company Profile

BCRX Company Information

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases.

BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases.

BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

North Carolina, USA

BCRX Key Officers

Key officers data coming soon

BCRX Company Profile

Biocryst Pharmaceuticals Inc (BCRX) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in North Carolina, USA.

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.

Market cap is $1.93B. There are 210.5M shares outstanding.

See the full Biocryst Pharmaceuticals Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if BCRX is a good investment.